Contraception and Reproductive Pharmacology

Contraception represents a critical component of reproductive health care, involving various pharmacological and mechanical approaches to prevent pregnancy. Understanding the hormonal regulation of the menstrual cycle is fundamental to comprehending how different contraceptive methods work.

The hypothalamic-pituitary-ovarian axis controls reproductive function through the coordinated release of gonadotropin-releasing hormone (GnRH), follicle-stimulating hormone (FSH), and luteinizing hormone (LH). During the menstrual cycle, estrogen and progesterone levels fluctuate, creating windows of fertility and infertility. Contraceptive methods exploit these hormonal fluctuations or create physical barriers to prevent fertilization and implantation.

Contraceptive efficacy is measured using the Pearl Index, which represents the number of pregnancies per 100 woman-years of exposure. Perfect use effectiveness differs significantly from typical use effectiveness, with user-dependent methods showing greater variation. For example, combined oral contraceptive pills (OCPs) have a perfect use failure rate of 0.3% but a typical use failure rate of 9%.

Modern contraceptive options include hormonal methods (OCPs, patches, rings, injections, implants), intrauterine devices (IUDs), barrier methods, and emergency contraception. Each method has distinct mechanisms of action, efficacy rates, side effect profiles, and contraindications. The choice of contraceptive method depends on multiple factors including patient preference, medical history, lifestyle factors, and desired duration of contraception.

Classification of Contraceptive Methods:

The pharmacokinetics of contraceptive hormones vary significantly between delivery methods. Oral preparations undergo first-pass hepatic metabolism, while transdermal patches provide steady-state hormone levels. Understanding these differences is crucial for selecting appropriate methods and counseling patients about potential drug interactions.

Oral contraceptive pills represent the most widely used reversible contraceptive method worldwide. OCPs are classified into combined hormonal contraceptives (CHCs) containing both estrogen and progestin, and progestin-only pills (POPs).

Combined Oral Contraceptives (COCs): COCs contain synthetic estrogen (typically ethinyl estradiol 10-50 μg) and various synthetic progestins. The primary mechanism involves suppression of the hypothalamic-pituitary-ovarian axis, preventing ovulation through inhibition of FSH and LH release. Secondary mechanisms include cervical mucus thickening, endometrial changes that reduce implantation likelihood, and altered fallopian tube motility.

COCs are further classified based on hormone dosing patterns:

• Monophasic: Constant hormone doses throughout the cycle
• Multiphasic: Variable hormone doses mimicking natural cycle fluctuations
• Extended cycle: Continuous hormone administration for 84-365 days

Progestin-Only Pills (POPs): POPs contain low-dose progestin without estrogen. The primary mechanism involves cervical mucus thickening and endometrial changes, with inconsistent ovulation suppression (approximately 60% of cycles). POPs require strict timing (within 3 hours of scheduled time) due to their short half-life.

Detailed OCP Pharmacology Table:

Benefits Beyond Contraception: COCs provide significant non-contraceptive benefits including reduction in ovarian and endometrial cancer risk, decreased menstrual blood loss, improvement in acne and hirsutism, and reduction in ovarian cysts. These benefits make COCs valuable for treating conditions like polycystic ovary syndrome (PCOS) and endometriosis.

Drug interactions are particularly important with OCPs. Enzyme-inducing medications (rifampin, certain anticonvulsants, St. John's wort) can reduce contraceptive efficacy by increasing hormone metabolism. Conversely, some antibiotics may theoretically reduce efficacy through gut flora disruption, though clinical significance remains debated.

Intrauterine devices represent the most effective form of reversible contraception, with efficacy rates exceeding 99%. Two main types exist: copper-containing IUDs and levonorgestrel-releasing intrauterine systems (LNG-IUS).

Copper IUDs: The copper T380A (ParaGard) contains 380 mm² of copper wire wound around the vertical stem and copper collars on the horizontal arms. Copper ions create a toxic environment for sperm and eggs through multiple mechanisms:

• Impairment of sperm motility and viability
• Interference with fertilization processes
• Alteration of endometrial environment preventing implantation
• Local inflammatory response enhancing contraceptive efficacy

Copper IUDs provide contraception for up to 10 years and can serve as emergency contraception when inserted within 120 hours of unprotected intercourse. The primary side effects include increased menstrual bleeding and cramping, particularly during the first 3-6 months after insertion.

Levonorgestrel-Releasing IUDs: LNG-IUS devices (Mirena, Skyla, Liletta, Kyleena) release 20 μg/day of levonorgestrel initially, decreasing over time. The primary mechanisms include:

• Cervical mucus thickening preventing sperm penetration
• Endometrial atrophy reducing implantation likelihood
• Partial ovulation suppression (varies by individual)
• Local progestin effects on fallopian tube function

IUD Comparison Table:

Clinical Advantages: IUDs offer numerous advantages including immediate reversibility, lack of user-dependent efficacy, minimal systemic hormone exposure (LNG-IUS), and cost-effectiveness over time. The LNG-IUS provides additional benefits for managing heavy menstrual bleeding, with 70-90% reduction in menstrual blood loss.

Insertion and Follow-up: IUD insertion requires proper timing (ideally during menstruation to confirm non-pregnancy) and sterile technique. Post-insertion follow-up includes string checks and evaluation for complications such as expulsion (2-5% risk) or perforation (<1% risk).

Long-acting hormonal contraceptives include subdermal implants and injectable formulations, providing highly effective contraception with minimal user intervention.

Subdermal Implants: The etonogestrel implant (Nexplanon/Implanon) consists of a single 4 cm rod containing 68 mg of etonogestrel in an ethylene vinyl acetate (EVA) core. The implant provides contraception for 3 years through continuous hormone release, with initial rates of 60-70 μg/day declining to 25-30 μg/day by the end of the first year.

Mechanism of Action:

1. Primary: Ovulation suppression through LH and FSH inhibition
2. Secondary: Cervical mucus thickening and endometrial changes
3. Systemic effects: Binding globulin changes affecting free hormone levels

Etonogestrel has high bioavailability (100%) and is metabolized primarily by the liver via CYP3A4. Peak serum levels occur within 8 hours of insertion, with contraceptive efficacy established within 8 hours when inserted during days 1-5 of the menstrual cycle.

Injectable Contraceptives: Depo-medroxyprogesterone acetate (DMPA) is administered as a 150 mg intramuscular injection every 12-13 weeks. The mechanism involves profound ovulation suppression through hypothalamic-pituitary axis inhibition.

Pharmacological Comparison Table:

Side Effect Profiles: Both methods commonly cause irregular bleeding patterns, with amenorrhea developing in 20-30% of implant users and 50-70% of DMPA users by one year. Weight gain concerns exist, particularly with DMPA (average 1-2 kg over 2 years). DMPA uniquely causes reversible bone mineral density reduction due to hypoestrogenism, requiring counseling about calcium and vitamin D supplementation.

Special Considerations: Implant removal requires a minor surgical procedure and may be complicated by deep insertion or fibrosis. DMPA's prolonged action means side effects persist until the medication clears, making it unsuitable for women desiring rapid return to fertility. Drug interactions with enzyme inducers (anticonvulsants, rifampin) can reduce implant efficacy but have minimal impact on DMPA due to its high dose and depot formulation.

Clinical Applications: These methods are particularly suitable for women desiring long-term contraception without estrogen exposure, those with compliance issues with daily methods, and adolescents requiring confidential contraception. The immediate reversibility of implants versus the delayed return to fertility with DMPA represents a key counseling point.

Emergency contraception provides a crucial backup option following unprotected intercourse or contraceptive failure. Available methods include oral medications and copper IUD insertion, each with distinct mechanisms, efficacy windows, and clinical considerations.

Levonorgestrel (Plan B): Levonorgestrel 1.5 mg is the most widely available emergency contraceptive, effective when taken within 72 hours of unprotected intercourse, though efficacy decreases significantly after 72 hours. The mechanism varies depending on the timing of administration relative to the menstrual cycle:

• Pre-ovulation: Delays or inhibits ovulation through LH surge suppression
• Peri-ovulation: May affect fertilization or early embryo development
• Post-ovulation: Minimal to no efficacy as it does not prevent implantation

Efficacy rates range from 85% when taken within 24 hours to 58% when taken 48-72 hours post-coitus. The medication has no teratogenic effects and does not terminate established pregnancies.

Ulipristal Acetate (ella): Ulipristal acetate 30 mg is a selective progesterone receptor modulator (SPRM) effective up to 120 hours post-coitus. Its mechanism involves:

• High-affinity progesterone receptor antagonism
• Delay or inhibition of ovulation even when taken during the LH surge
• Potential effects on endometrial receptivity

Ulipristal demonstrates superior efficacy compared to levonorgestrel, particularly in the 72-120 hour window, with maintained effectiveness of approximately 85% throughout the 120-hour period.

Emergency Contraception Comparison:

Copper IUD as Emergency Contraception: Copper IUD insertion within 120 hours represents the most effective emergency contraceptive method, with efficacy exceeding 99%. The mechanism involves copper ion toxicity to sperm and eggs, along with inflammatory changes preventing implantation. This method provides the added benefit of ongoing contraception for up to 10 years.

Clinical Considerations:

• Drug Interactions: Enzyme-inducing medications may reduce emergency contraceptive efficacy
• Repeat Use: Neither levonorgestrel nor ulipristal should be used as regular contraception due to inferior efficacy compared to ongoing methods
• Follow-up: Patients should be counseled about expected menstrual changes and advised to take a pregnancy test if menses is delayed >1 week

Contraindications and Side Effects: Emergency contraceptives have few absolute contraindications, with known pregnancy being the primary limitation (due to lack of efficacy rather than harm). Common side effects include nausea (20-25%), fatigue, headache, and menstrual irregularities. Ulipristal may delay menstruation more than levonorgestrel.

Counseling Points: Patients should understand that emergency contraception is less effective than ongoing contraceptive methods and should be counseled about transitioning to regular contraception after emergency contraceptive use.

Fertility medications play essential roles in treating infertility and supporting assisted reproductive technologies (ART). These drugs manipulate the hypothalamic-pituitary-ovarian axis to stimulate ovulation, enhance follicular development, or support early pregnancy.

Ovulation Induction Agents:

Clomiphene Citrate: Clomiphene is a selective estrogen receptor modulator (SERM) that acts as an estrogen antagonist at the hypothalamus, blocking negative feedback and stimulating FSH and LH release. The typical regimen involves 50-150 mg daily for 5 days, usually starting on cycle days 3-5. Ovulation occurs 5-10 days after the last clomiphene dose in 70-80% of appropriately selected patients.

Mechanism: Competitive inhibition of estrogen receptors in the hypothalamus leads to increased GnRH secretion, subsequently increasing FSH and LH release, promoting follicular development and ovulation.

Letrozole: Letrozole, an aromatase inhibitor, reduces estrogen production by blocking the conversion of androgens to estrogens. This creates a hypoestrogenic state that stimulates FSH release. Letrozole 2.5-7.5 mg daily for 5 days has emerged as first-line therapy for ovulation induction in PCOS patients due to higher live birth rates compared to clomiphene.

Gonadotropin Therapy: Direct gonadotropin administration bypasses hypothalamic-pituitary regulation:

Injectable Gonadotropins:

• FSH preparations (Gonal-F, Follistim): Recombinant FSH for follicular stimulation
• hMG (Menopur): Contains both FSH and LH activity from postmenopausal urine
• hCG (Pregnyl, Ovidrel): LH-like activity for ovulation triggering

Fertility Drug Classification Table:

GnRH Modulators:

GnRH Agonists (Leuprolide, Nafarelin): Initially stimulate, then suppress the pituitary through receptor downregulation. Used in IVF protocols to prevent premature ovulation and in treating endometriosis. The "flare" effect initially increases FSH/LH, followed by suppression after 7-14 days.

GnRH Antagonists (Cetrorelix, Ganirelix): Provide immediate competitive inhibition of GnRH receptors without initial flare. Used in IVF cycles to prevent premature LH surges while allowing controlled follicular development.

Ovarian Hyperstimulation Syndrome (OHSS): OHSS represents a potentially life-threatening complication of fertility treatments, characterized by:

• Ovarian enlargement and increased vascular permeability
• Fluid shifts causing ascites, pleural effusions, and hemoconcentration
• Risk factors: PCOS, young age, high estradiol levels, multiple follicles
• Management: Conservative care for mild cases, hospitalization for severe cases

Clinical Applications:

• Anovulatory infertility: Clomiphene or letrozole first-line
• IVF cycles: Gonadotropins with GnRH modulators
• Male factor infertility: hCG and FSH for spermatogenesis enhancement
• Luteal phase support: Progesterone supplementation in ART cycles

Monitoring Requirements: Fertility treatments require intensive monitoring including serial transvaginal ultrasounds, serum estradiol levels, and LH measurements to optimize timing and minimize complications.

Understanding drug interactions, contraindications, and individual patient factors is crucial for safe and effective contraceptive prescribing. This knowledge enables clinicians to make evidence-based recommendations tailored to each patient's medical history and preferences.

Major Drug Interactions:

Enzyme-Inducing Medications: Certain drugs significantly reduce contraceptive hormone levels through hepatic enzyme induction:

• Anticonvulsants: Carbamazepine, phenytoin, phenobarbital, topiramate
• Antimicrobials: Rifampin, rifabutin, griseofulvin
• Herbal preparations: St. John's wort
• HIV medications: Efavirenz, nevirapine, ritonavir-boosted protease inhibitors

These interactions primarily affect oral, transdermal, and vaginal hormone delivery methods. Injectable DMPA and implants show variable susceptibility, while IUDs remain unaffected due to local hormone action.

Management Strategies:

1. Alternative contraception: Recommend IUDs or barrier methods
2. Dose adjustment: Higher hormone doses (rarely used)
3. Additional protection: Concurrent barrier methods
4. Method switching: Transition to non-hormonal options

Contraindications to Hormonal Contraception:

Absolute Contraindications (WHO Category 4):

• Active or history of venous thromboembolism
• Acute myocardial infarction or ischemic heart disease
• Cerebrovascular disease
• Migraine with aura (for combined hormonal methods)
• Active liver disease or liver tumors
• Breast cancer (current or history)
• Unexplained vaginal bleeding

Relative Contraindications (WHO Category 3):

• Multiple cardiovascular risk factors
• Hypertension (≥160/100 mmHg)
• Diabetes with vascular complications
• Inflammatory bowel disease with complications
• Certain drug interactions

Cardiovascular Risk Assessment:

Thrombotic Risk Factors: Combined hormonal contraceptives increase venous thromboembolism risk 3-6 fold, with baseline risk of 1-2 per 10,000 woman-years. Risk factors include:

• Personal/family history of thrombosis
• Inherited thrombophilias (Factor V Leiden, prothrombin mutations)
• Immobilization, surgery
• Age >35 years with smoking
• Obesity (BMI >30 kg/m²)

Clinical Decision-Making Framework:

Special Populations:

Adolescents:

• No medical restrictions for hormonal contraception
• Consider long-acting methods (IUDs, implants) for efficacy
• Address concerns about weight gain, acne, mood changes
• Confidentiality and access considerations

Postpartum Contraception:

• Immediate postpartum: IUD insertion (within 48 hours) or progestin-only methods
• Breastfeeding: Avoid combined hormonal methods for 6 weeks
• Non-breastfeeding: Combined methods after 3 weeks

Perimenopausal Women:

• Continue contraception until menopause confirmed
• Consider non-hormonal methods or low-dose hormonal options
• Benefits may outweigh risks for appropriate candidates

Monitoring and Follow-up: Establish appropriate follow-up schedules based on method choice and risk factors. Annual visits should include blood pressure monitoring, symptom assessment, and discussion of method satisfaction. Encourage patients to report concerning symptoms promptly, particularly signs of thrombosis, liver dysfunction, or mood changes.